

Development of Legislation and Other Instruments

BPC-34: Minority opinion on BPC opinion on glyoxal (PTs 2, 3 and 4)

The application for approval for the substance glyoxal lacks sufficient information to determine whether the substance should be classified as carcinogenic in category 1A or 1B or mutagenic in category 1A or 1B, respectively. In the absence of the necessary information, it is not possible to judge whether the substance meets the exclusion criteria set out in Article 5 (1) or is a candidate substance for substitution under Article 10 (1), in case it may be approved in accordance with Article 5(2).

According to the EU Biocidal Regulation Articles 6(2) and 8(2), the evaluating competent authority shall require that the applicant provides sufficient information to make it possible to determine whether an active substance meets any of the exclusion criteria or is a candidate substance for substitution. This has not been done in the present case.

One of the aims of the EU Biocidal Products Regulation is to ensure a high level of protection for human health, animal health and the environment. Furthermore, the regulation is underpinned by the precautionary principle. Against this background, an active substance should not be approved unless it has been determined whether it meets any of the exclusion criteria or is a candidate substance for substitution.

Since the Committee decided in its opinion to suggest approval of glyoxal (PTs 2, 3 and 4), Sweden voted against the proposal and submits a minority opinion.